Pricing Pressure and Dollar Drag Overshadow Munich Re’s Record Quarter

Munich Re's stock hovers near 52-week low despite €900M buyback and insider purchases, as analyst downgrades and currency headwinds weigh on sentiment.

The message from Munich Re’s boardroom is unmistakably bullish, yet the stock refuses to respond. Three executives loaded up on shares in mid-May, and the company launched a fresh €900 million buyback tranche on May 14, but the stock price remains within a whisker of its 52-week low of €467.80. At Friday’s close of €475, the equity has shed 13.48% since the start of 2025, and the 30-day decline stands at a painful 16.79%.

The buyback programme, which started immediately, aims to acquire own shares worth up to €900 million by August 21. That marks the first slice of a larger €2.25 billion repurchase mandate that runs until the next annual general meeting. All bought-back shares are destined for cancellation, a move that bolsters earnings per share. The capital return strategy also features a €24.00 dividend for fiscal 2025, up from the previous year.

Two days before the buyback began, three board members acted directly. On May 12, Dr. Achim Kassow, Stefan Golling and Dr. Markus Rieß together spent roughly €580,000 on Munich Re equity, with purchases reported to the market the following day. Kassow invested around €141,000, while Golling and Rieß each paid €476.19 and €476.50 per share respectively. Insider transactions are seldom a guarantee of an immediate bounce, but they signal that senior management considers the current valuation attractive.

That confidence stands in stark contrast to the caution emanating from the analyst community. The Erste Group downgraded Munich Re from “Strong Buy” to “Hold” on May 14, citing the latest quarterly figures. Goldman Sachs retains a “Neutral” stance, and while the DZ Bank kept its “Buy” rating, it trimmed the fair-value estimate from €640 to €625. The message is mixed: operational performance is solid, but the valuation no longer receives the same tailwind.

Indeed, the first-quarter numbers themselves gave little reason for alarm. Net profit surged 57% year-on-year to €1.714 billion, while operating earnings climbed to €2.23 billion. Lower major losses were the primary engine behind the improvement. Yet the top line tells a more subdued story. Revenue from insurance contracts slipped by nearly €800 million to €15 billion, as reinsurance premiums written in US dollars lost value when translated back into euros. Currency headwinds were not the only drag: inflation-adjusted reinsurance prices fell 3.1%, pointing to intensifying competition that could squeeze margins further down the road.

The Iran conflict added a one-off charge of around €90 million to the quarterly result, but management is holding firm on its full-year outlook. The group still targets a net profit of €6.3 billion for 2025. Underpinning that ambition is an aggressive cost-cutting programme at subsidiary ERGO, where roughly 200 positions per year will be eliminated through natural attrition, partial retirement and severance packages. Around 1,000 jobs are set to disappear by 2030, with compulsory redundancies ruled out. The restructuring supports the broader goal of saving €600 million annually by the end of the decade.

For now, the share price is caught between competing forces. The strength of the underlying earnings and the hefty capital returns argue for a floor, while the price erosion and dollar sensitivity keep buyers hesitant. The market is watching two key variables: the trajectory of pricing and claims, and whether the buyback can eventually close the gap between the company’s performance and its valuation. Until those uncertainties resolve, every management signal – whether from the trading floor or the boardroom – will be scrutinised as a clue to the next move.